Other biomarkers for detecting prostate cancer

BJU International

Volumn 105, Issue 2, 2010, Pages 166-169

  Nogueira, Lucas ^a,b   Corradi, Renato ^c   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Hospital Governador Israel Pinheiro   (Brazil)

Author keywords

Prostate biomarkers; Prostate biopsy; Prostate cancer; PSA

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BIOLOGICAL MARKER; GLUTATHIONE TRANSFERASE P1; KALLIKREIN; KALLIKREIN 2; PLASMINOGEN ACTIVATOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

ANTIGEN SPECIFICITY; CANCER DIAGNOSIS; CLINICAL EDUCATION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; EARLY CANCER; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SHORT SURVEY;

HUMANS; MALE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 74049134878     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09088.x     Document Type: Short Survey

References (26)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96
2. Ries LAG, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD : National Cancer Institute. Available at: http://seer.cancer.gov/csr/-2004/. Accessed May 2009, based on November 2006 SEER data submission, posted to the SEER web site, 2007
3. Ung JO, Richie JP, Chen MH, Renshaw AA, D'Amico AV. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002 60 : 458 463
4. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005 294 : 66 70 (Pubitemid 41002840)
5. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003 349 : 215 224
6. Klein LT, Lowe FC. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am 1997 24 : 293 297
7. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004 172 : 1297 1301
8. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002 59 : 797 802
9. Darson MF, Pacelli A, Roche P et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999 53 : 939 944 (Pubitemid 29196309)
10. Lintula S, Stenman J, Bjartell A, Nordling S, Stenman UH. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005 63 : 324 329
11. Steuber T, Vickers AJ, Serio AM et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007 53 : 233 240
12. Stephens RW, Nielsen HJ, Christensen IJ et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999 91 : 869 874
13. Shariat SF, Roehrborn CG, McConnell JD et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007 25 : 349 355
14. Steuber T, Vickers A, Haese A et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 2007 120 : 1499 1504
15. Elgamal AA, Holmes EH, Su SL et al. Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 2000 18 : 10 6
16. Chang SS, Gaudin PB, Reuter VE, Heston WD. Prostate-specific membrane antigen: present and future applications. Urology 2000 55 : 622 629
17. Dhir R, Vietmeier B, Arlotti J et al. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004 171 : 1419 1423
18. Leman ES, Cannon GW, Trock BJ et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007 69 : 714 720
19. Bradley SV, Oravecz-Wilson KI, Bougeard G et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res 2005 65 : 4126 4133
20. Minelli A, Ronquist G, Carlsson L, Mearini E, Nilsson O, Larsson A. Antiprostasome antibody titres in benign and malignant prostate disease. Anticancer Res 2005 25 : 4399 4402
21. Wang X, Yu J, Sreekumar A et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005 353 : 1224 1235
22. de Kok JB, Verhaegh GW, Roelofs RW et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002 62 : 2695 2698
23. Hessels D, Klein Gunnewiek JM, van Oort I et al. DD3 (PCA3) -based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003 44 : 8 15
24. Deras IL, Aubin SM, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008 179 : 1587 1592
25. Harden SV, Sanderson H, Goodman SN et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003 95 : 1634 1637
26. Hoque MO, Topaloglu O, Begum S et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005 23 : 6569 6575